Management and prevention of agranulocytosis in patients receiving clozapine | Zendy

Mebanga Ojong | Zendy; Shari N. Allen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Management and prevention of agranulocytosis in patients receiving clozapine

Author(s) -

Mebanga Ojong,

Shari N. Allen

Publication year - 2013

Publication title -

mental health clinician

Language(s) - English

Resource type - Journals

ISSN - 2168-9709

DOI - 10.9740/mhc.n166825

Subject(s) - clozapine , medicine , schizophrenia (object oriented programming) , adverse effect , antipsychotic , atypical antipsychotic , white blood cell , leukopenia , neutropenia , pediatrics , intensive care medicine , psychiatry , chemotherapy

Clozapine is an antipsychotic associated with superior efficacy compared to other atypical antipsychotics in the treatment of schizophrenia. However, clozapine use is limited due to its association with a rare but potentially fatal adverse effect, agranulocytosis. Patients receiving clozapine therapy require frequent monitoring of white blood cell (WBC) and absolute neutrophil counts (ANC). This article reviews the monitoring parameters for patients receiving clozapine therapy, and the management and prevention of clozapine-associated agranulocytosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research